InsiderSignalSign in

← Insider buys

BEAM

Beam Therapeutics Inc. · Healthcare

Insiders sold $19.7M of Beam Therapeutics Inc. in the last 12 months and bought none

$0Bought, 12 mo

$19.7MSold, 12 mo

$2.6BMarket cap

BEAM over the last year

No insider buys filed in this year

BEAM after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Every filing

69 insider filings since 2021, newest first

John M. Evans · CEO

$1.2M−4.6%Oct 16

Amy Simon · Chief Medical Officer

$429K−16.3%Jul 29

John M. Evans · CEO

$1.7M−4.6%Jul 1

FMR LLC · See Remark 1

$10.0M−25.0%Jun 29

John M. Evans · CEO

$739K−3.0%Apr 6

Amy Simon · Chief Medical Officer

$165K−6.0%Apr 6

Bethany J Cavanagh · SVP, Finance, Treasurer

$80K−6.0%Apr 6

Christine Bellon · General Counsel

$146K−5.0%Apr 6

Giuseppe Ciaramella · President

$290K−5.0%Apr 6

John M. Evans · CEO

$1.1M−4.0%Apr 1

Giuseppe Ciaramella · President

$1.1M−16.0%Feb 26

John M. Evans · CEO

$1.4M−4.0%Feb 2

Bethany J Cavanagh · SVP, Finance, Treasurer

$217K−15.0%Jan 26

Christine Bellon · General Counsel

$47K−1.0%Jan 26

Bethany J Cavanagh · SVP, Finance, Treasurer

$91K−7.0%Jan 21

Christine Bellon · General Counsel

$645K−16.0%Jan 20

Sravan Kumar Emany · CFO

$171K−8.0%Jan 5

Christine Bellon · General Counsel

$34K−1.0%Jan 5

Giuseppe Ciaramella · President

$1.3M−32.0%Nov 8

Giuseppe Ciaramella · President

$1.3M−24.0%Oct 16

John M. Evans · CEO

$1.5M−5.0%Oct 2

Amy Simon · Chief Medical Officer

$29K−2.0%Jul 3

John M. Evans · CEO

$1.5M−5.0%Jun 28

Amy Simon · Chief Medical Officer

$735K−25.0%Apr 3

Christine Bellon · General Counsel

$109K−3.0%Apr 3

John M. Evans · CEO

$582K−2.0%Apr 3

Giuseppe Ciaramella · President

$146K−3.0%Apr 3

Terry-Ann Burrell · CFO

$175K−7.0%Apr 3

John M. Evans · CEO

$2.0M−5.0%Apr 1

Fmr LLC · See Remark 1

$27.5M−18.0%Feb 15

John M. Evans · CEO

$1.5M−5.0%Feb 2

Christine Bellon · General Counsel

$50K−2.0%Jan 5

Christine Bellon · General Counsel

$305K−11.0%Nov 22

Amy Simon · Chief Medical Officer

$64K−5.0%Nov 1

Giuseppe Ciaramella · President and CSO

$5.0M−76.0%Jul 25

John M. Evans · CEO

$345K−1.0%Apr 5

Giuseppe Ciaramella · President and CSO

$109K−3.0%Apr 5

Christine Bellon · General Counsel

$62K−2.0%Apr 5

Amy Simon · Chief Medical Officer

$481K−19.0%Apr 5

Terry-Ann Burrell · CFO

$138K−9.0%Apr 5

Terry-Ann Burrell · CFO

$1.7M−54.0%Jan 30

Terry-Ann Burrell · CFO

$911K−39.0%Jan 25

Terry-Ann Burrell · CFO

$2.1M−60.0%Jan 20

Giuseppe Ciaramella · President and CSO

$2.0M−36.0%Jan 5

Giuseppe Ciaramella · President and CSO

$2.2M−36.0%Dec 14

John M. Evans · CEO

$2.3M−4.0%Nov 2

Fmr LLC · See Remark 1, 10%

Fmr LLC · See Remark 1, 10%

John M. Evans · CEO

$3.3M−4.0%Jul 29

John M. Evans · CEO

$1.9M−4.0%May 2

About Beam Therapeutics Inc.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.